Targeting IKKβ in Cancer: Challenges and Opportunities for the Therapeutic Utilisation of IKKβ Inhibitors
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Deregulated NF-κB signalling is implicated in the pathogenesis of numerous human inflammatory disorders and malignancies. Consequently, the NF-κB pathway has attracted attention as an attractive therapeutic target for drug discovery. As the primary, druggable mediator of canonical NF-κB signalling the IKKβ protein kinase has been the historical focus of drug development pipelines. Thousands of compounds with activity against IKKβ have been characterised, with many demonstrating promising efficacy in pre-clinical models of cancer and inflammatory disease. However, severe on-target toxicities and other safety concerns associated with systemic IKKβ inhibition have thus far prevented the clinical approval of any IKKβ inhibitors. This review will discuss the potential reasons for the lack of clinical success of IKKβ inhibitors to date, the challenges associated with their therapeutic use, realistic opportunities for their future utilisation, and the alternative strategies to inhibit NF-κB signalling that may overcome some of the limitations associated with IKKβ inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NF-κB signaling in inflammation
Liu, T., Zhang, L., Joo, D., & Sun, S.-C. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.23 · Cited by 8,791
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025 · cited 1×
“A key feature of tumour immune evasion is the increased expression of certain ligands, notably programmed cell death-ligand 1 (PD-L1), at the cell surface of cancer cells and immune cells, such as dendritic cells and macrophages [200,201].”
BackgroundNF-κB regulation in the immune system
Li, Q., & Verma, I. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri910 · Cited by 4,007
NF-κB: a key role in inflammatory diseases
Tak, P. P., & Firestein, G. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11830 · Cited by 3,918
NF-κB, inflammation, immunity and cancer: coming of age
Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679
IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z.-W., Egan, L. J., Kagnoff, M. F., & Karin, M. (2004) · Cell · doi:10.1016/j.cell.2004.07.013 · Cited by 2,433
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
Integrating cell-signalling pathways with NF-κB and IKK function
Perkins, N. D. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2083 · Cited by 2,350
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898 · cited 1×
“Furthermore, IL-1β is required for immunogenic cell death (ICD)-mediated dendritic cell (DC) maturation and antigen presentation as part of the adaptive immune response [163].”
BackgroundNF-κB, the first quarter-century: remarkable progress and outstanding questions
Hayden, M. S., & Ghosh, S. (2012) · Genes & Development · doi:10.1101/gad.183434.111 · Cited by 1,693
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
Erez, N., Truitt, M., Olson, P., & Hanahan, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.041 · Cited by 1,515 · cited 1×
“However, these findings directly contrast with other studies where IKKβ ablation in mesenchymal cells protected against inflammation-induced intestinal carcinogenesis [165,166].”
ResultControl of IκB-α Proteolysis by Site-Specific, Signal-Induced Phosphorylation
Brown, K., Gerstberger, S., Carlson, L., Franzoso, G., & Siebenlist, U. (1995) · Science · doi:10.1126/science.7878466 · Cited by 1,434
NF-κB, an Active Player in Human Cancers
Xia, Y., Shen, S., & Verma, I. M. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0112 · Cited by 1,213
NF-κB Restricts Inflammasome Activation via Elimination of Damaged Mitochondria
Zhong, Z., Umemura, A., Sanchez-Lopez, E., Liang, S., Shalapour, S., Wong, J., He, F., Boassa, D., Perkins, G., Ali, S. R., et al. (2016) · Cell · doi:10.1016/j.cell.2015.12.057 · Cited by 1,197
Proteasome inhibitors in cancer therapy
Manasanch, E. E., & Orlowski, R. Z. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.206 · Cited by 1,024 · cited 1×
“It is also unclear to what extent the clinical response to proteasome inhibitors in lymphomas results from the inhibition of NF-κB signalling [243].”
BackgroundIκB Kinase Promotes Tumorigenesis through Inhibition of Forkhead FOXO3a
Hu, M. C.-T., Lee, D.-F., Xia, W., Golfman, L. S., Ou-Yang, F., Yang, J.-Y., Zou, Y., Bao, S., Hanada, N., Saso, H., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00302-2 · Cited by 868
Deubiquitination and Stabilization of PD-L1 by CSN5
Lim, S.-O., Li, C.-W., Xia, W., Cha, J.-H., Chan, L.-C., Wu, Y., Chang, S.-S., Lin, W.-C., Hsu, J.-M., Hsu, Y.-H., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.010 · Cited by 793
“Re-educating” tumor-associated macrophages by targeting NF-κB
Hagemann, T., Lawrence, T., McNeish, I., Charles, K. A., Kulbe, H., Thompson, R. G., Robinson, S. C., & Balkwill, F. R. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080108 · Cited by 792
Inhibiting NF-κB activation by small molecules as a therapeutic strategy
Gupta, S. C., Sundaram, C., Reuter, S., & Aggarwal, B. B. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2010.05.004 · Cited by 762
Perkins, N. D. (2006) · Oncogene · doi:10.1038/sj.onc.1209937 · Cited by 674
Greten, F. R., Arkan, M. C., Bollrath, J., Hsu, L.-C., Goode, J., Miething, C., Göktuna, S. I., Neuenhahn, M., Fierer, J., Paxian, S., et al. (2007) · Cell · doi:10.1016/j.cell.2007.07.009 · Cited by 616 · cited 3×
“For example, a series of seminal studies demonstrated a role for NF-κB signalling in the negative control of inflammasome-dependent IL-1β secretion [159,160].”
BackgroundResultNF-κB Directs Dynamic Super Enhancer Formation in Inflammation and Atherogenesis
Brown, J. D., Lin, C. Y., Duan, Q., Griffin, G., Federation, A. J., Paranal, R. M., Bair, S., Newton, G., Lichtman, A. H., Kung, A. L., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.08.024 · Cited by 614 · cited 1×
“of pro-inflammatory NF-κB-dependent transcriptional responses using inhibitors of the epigenetic modifiers bromodomain and extra-terminal (BET) proteins, such as JQ1, exhibited synergistic effects alongside JAK/STAT inhibition in myeloproliferative neoplasms [251,252].”
BackgroundGuiducci, C., Vicari, A. P., Sangaletti, S., Trinchieri, G., & Colombo, M. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4262 · Cited by 549
Staudt, L. M. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000109 · Cited by 485
Reynaert, N. L., van der Vliet, A., Guala, A. S., McGovern, T., Hristova, M., Pantano, C., Heintz, N. H., Heim, J., Ho, Y.-S., Matthews, D. E., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603290103 · Cited by 442
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
Bivona, T. G., Hieronymus, H., Parker, J., Chang, K., Taron, M., Rosell, R., Moonsamy, P., Dahlman, K., Miller, V. A., Costa, C., et al. (2011) · Nature · doi:10.1038/nature09870 · Cited by 396 · cited 1×
“For example, activation of NF-κB has been strongly linked to intrinsic and acquired resistance to epidermal growth factor receptor (EGFR) inhibitors [181,194,195], while synergistic cytotoxicity has been observed in ABC DLBCL treated with JAK and IKKβ inhibitors [196].”
BackgroundTNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
Bertrand, F., Montfort, A., Marcheteau, E., Imbert, C., Gilhodes, J., Filleron, T., Rochaix, P., Andrieu-Abadie, N., Levade, T., Meyer, N., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02358-7 · Cited by 384 · cited 1×
“Nonetheless, this approach has received some support by the observation that TNFα-blockade overcomes resistance to anti-PD-1 in experimental melanoma [209].”
ResultAn integrin β3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition
Seguin, L., Kato, S., Franovic, A., Camargo, M. F., Lesperance, J., Elliott, K. C., Yebra, M., Mielgo, A., Lowy, A. M., Husain, H., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb2953 · Cited by 374
Inflammation and the Metabolic Syndrome: The Tissue-Specific Functions of NF-κB
Catrysse, L., & van Loo, G. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.01.006 · Cited by 329 · cited 1×
“The number of conditions where IKKβ inhibitors are being pursued as a treatment option was too great to cover here but includes: obesity-associated metabolic disease [253], atherosclerosis [254], multiple sclerosis [255], COPD [256], muscular dystrophy [257], Parkinson’s disease [258], inflammatory bowel disease [259]…”
BackgroundNovel cross-talk within the IKK family controls innate immunity
Clark, K., Peggie, M., Plater, L., Sorcek, R. J., Young, E. R. R., Madwed, J. B., Hough, J., McIver, E. G., & Cohen, P. (2011) · Biochemical Journal · doi:10.1042/bj20101701 · Cited by 326 · cited 3×
“The selectivity of BI605906 for IKKβ over 100 other serine/threonine and tyrosine kinases has also been confirmed [40], while MLN-120B exhibited a highly favourable selectivity profile when tested against a panel of 442 kinases [99], making these inhibitors the preferred tools for dissecting IKKβ-dependent functions […”
BackgroundNF-κB c-Rel Is Crucial for the Regulatory T Cell Immune Checkpoint in Cancer
Grinberg-Bleyer, Y., Oh, H., Desrichard, A., Bhatt, D. M., Caron, R., Chan, T. A., Schmid, R. M., Klein, U., Hayden, M. S., & Ghosh, S. (2017) · Cell · doi:10.1016/j.cell.2017.08.004 · Cited by 297 · cited 1×
“, anti-PD1 therapy) to enhance anti-tumour immunity in a melanoma model [248].”
BackgroundKleppe, M., Koche, R., Zou, L., van Galen, P., Hill, C. E., Dong, L., De Groote, S., Papalexi, E., Hanasoge Somasundara, A. V., Cordner, K., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.11.009 · Cited by 279
Requirement of the NF-κB Subunit p65/RelA for K-Ras–Induced Lung Tumorigenesis
Bassères, D. S., Ebbs, A., Levantini, E., & Baldwin, A. S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4290 · Cited by 189 · cited 1×
“Significantly, IKKβ-dependent NF-κB activation in these models has been shown to drive lung tumourigenesis, primarily through enhanced cancer cell proliferation [65,178,179].”
BackgroundNeutrophil-Derived IL-1β Impairs the Efficacy of NF-κB Inhibitors against Lung Cancer
McLoed, A. G., Sherrill, T. P., Cheng, D.-S., Han, W., Saxon, J. A., Gleaves, L. A., Wu, P., Polosukhin, V. V., Karin, M., Yull, F. E., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.085 · Cited by 107
Cited by
NF-κB: At the Borders of Autoimmunity and Inflammation
Barnabei, L., Laplantine, E., Mbongo, W., Rieux-Laucat, F., & Weil, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.716469 · Cited by 630
Regulation of PD-L1 Expression by NF-κB in Cancer
Antonangeli, F., Natalini, A., Garassino, M. C., Sica, A., Santoni, A., & Di Rosa, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584626 · Cited by 385
Cuollo, L., Antonangeli, F., Santoni, A., & Soriani, A. (2020) · Biology · doi:10.3390/biology9120485 · Cited by 291
Targeting NF-κB Signaling for Multiple Myeloma
Wong, A. H.-H., Shin, E. M., Tergaonkar, V., & Chng, W.-J. (2020) · Cancers · doi:10.3390/cancers12082203 · Cited by 42
Central role for cholangiocyte pathobiology in cholestatic liver diseases
Jalan-Sakrikar, N., Guicciardi, M. E., O’Hara, S. P., Azad, A., LaRusso, N. F., Gores, G. J., & Huebert, R. C. (2025) · Hepatology · doi:10.1097/hep.0000000000001093 · Cited by 38
Metadata
- Authors
- Prescott, J. A., & Cook, S. J.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2018-08-23
- Volume
- 7
- Issue
- 9
- Pages
- 115
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W2888749522
- Cited by
- 139
- References
- 35
- FWCI
- 3.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.